Roche teams up with Tekmira to develop RNAi treatments

05/11/2009 | Financial Post (Canada) ·

Roche Holding tapped Tekmira Pharmaceuticals to help develop its first two RNA interference-based drugs. The deal grants Roche access to Tekmira's stable nucleic acid lipid particle technology and entitles Tekmira to an upfront payment of about $18.4 million as well as additional milestone payments and royalties.

View Full Article in:

Financial Post (Canada) ·

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX